[Antihyperlipidemic actions in the treatment of nephropathies].
In view of weak implication of immunoinflammatory mechanisms in pathogenesis of noninflammatory nephropathy one may expect the disease course improvement and more slow progression of renal dysfunction. The mechanism of this action can be realized through hypolipidemic effect. In recent research there are data on a direct lovastatin action on the mechanism underlying nephritis progression by means of inhibiting proliferation of mesangial cells.
D000293:Adolescent; D000328:Adult; D000368:Aged; D002908:Chronic Disease; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000178:diet therapy / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D007674:Kidney Diseases / Q000178:diet therapy / Q000188:drug therapy*; D008148:Lovastatin / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D012074:Remission Induction
D000960:Hypolipidemic Agents; D008148:Lovastatin
Antigiperlipidemicheskie vozdeĭstviia pri lechenii nefropatiĭ.